Todos os artigos
Miscellaneous

The Rise of Drug-Resistant Tuberculosis: What India Needs to Know

India faces a growing challenge with drug-resistant TB strains. Here's what clinicians and patients should know about this emerging threat.

By Dr. Mohan Gayen
2 min de leitura36 views

Educational use only — not medical advice. Ler o aviso legal completo.

The Rise of Drug-Resistant Tuberculosis: What India Needs to Know

India bears the highest burden of tuberculosis (TB) globally, accounting for 27% of all TB cases worldwide. In recent years, the emergence of drug-resistant TB strains has added a new layer of complexity to this public health challenge.

What Is Drug-Resistant TB?

Drug-resistant TB occurs when Mycobacterium tuberculosis develops resistance to one or more anti-TB drugs. The two main types are:

  • Multidrug-resistant TB (MDR-TB): Resistant to at least isoniazid and rifampicin
  • Extensively drug-resistant TB (XDR-TB): Resistant to isoniazid, rifampicin, plus any fluoroquinolone and at least one second-line injectable drug

Key Point

Drug-resistant TB requires longer, more complex treatment regimens with lower success rates.

Why Is India Particularly Vulnerable?

Several factors contribute to India's heightened risk:

  1. High TB burden: More cases mean more opportunities for resistance to develop
  2. Incomplete treatment: Patients often stop medication when symptoms improve
  3. Over-the-counter availability: Easy access to TB drugs promotes inappropriate use
  4. Crowded living conditions: Facilitates rapid transmission of resistant strains

Red Flags for Clinicians

Consider drug-resistant TB when:

  • Persistent symptoms despite standard treatment
  • Known contact with a drug-resistant TB case
  • Treatment failure in a previously treated patient

Emergency

Any patient suspected of drug-resistant TB requires immediate referral to a specialist center.

What Can Be Done?

Prevention and control strategies include:

  1. Strict adherence to Directly Observed Treatment, Short-course (DOTS)
  2. Rapid diagnosis using molecular tests like CBNAAT
  3. Infection control measures in healthcare settings
  4. Public education about completing TB treatment

Clinical Pearl

Always ask about previous TB treatment - it's a key risk factor for drug resistance.

The Road Ahead

India's National TB Elimination Programme has set ambitious goals to eliminate TB by 2025. Addressing drug resistance is crucial to achieving this target. This requires:

  • Strengthening laboratory capacity
  • Expanding access to new drugs
  • Improving treatment adherence support

Sources

The World Health Organization's Global TB Report 2023 provides the latest data on drug-resistant TB. India's National TB Elimination Programme outlines the national strategy for addressing this challenge.

Medical Disclaimer

This content is intended for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions should be made by a qualified healthcare professional after appropriate evaluation of the individual patient. The information provided may not apply to every clinical situation and should be interpreted in the context of current guidelines and clinical judgment.

© 2026 Dr. Mohan Gayenwww.drmohangayen.com

Copyright 2026 Dr. Mohan Gayen. Official website: www.drmohangayen.com.

Comments

Back to Homepage